Cargando…
Human/SARS-CoV-2 genome-scale metabolic modeling to discover potential antiviral targets for COVID-19
BACKGROUND: Coronavirus disease 2019 (COVID-19) has caused a substantial increase in mortality and economic and social disruption. The absence of US Food and Drug Administration–approved drugs for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) highlights the need for new therapeutic dr...
Autores principales: | Wang, Feng-Sheng, Chen, Ke-Lin, Chu, Sz-Wei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taiwan Institute of Chemical Engineers. Published by Elsevier B.V.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8843340/ https://www.ncbi.nlm.nih.gov/pubmed/35186172 http://dx.doi.org/10.1016/j.jtice.2022.104273 |
Ejemplares similares
-
Fuzzy optimization for identifying antiviral targets for treating SARS-CoV-2 infection in the heart
por: Chu, Sz-Wei, et al.
Publicado: (2023) -
Genome‐scale metabolic modeling reveals SARS‐CoV‐2‐induced metabolic changes and antiviral targets
por: Cheng, Kuoyuan, et al.
Publicado: (2021) -
Genome-scale metabolic modeling reveals SARS-CoV-2-induced metabolic changes and antiviral targets
por: Cheng, Kuoyuan, et al.
Publicado: (2021) -
Genome-Scale Metabolic Model of Infection with SARS-CoV-2 Mutants Confirms Guanylate Kinase as Robust Potential Antiviral Target
por: Renz , Alina, et al.
Publicado: (2021) -
SARS-CoV-2: An Update on Potential Antivirals in Light of SARS-CoV Antiviral Drug Discoveries
por: Elshabrawy, Hatem A.
Publicado: (2020)